Barclays raises target for Amgen stock from USD 380.00 to USD 400.00

Published on 10/26/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 10.05 billion on June 30, 2026. Amgen stock costs EUR 393.95 on October 26, 2026, down 1.71 percent versus Xetra close.

Analyst target and reporting date

Barclays raised its Amgen target from USD 380.00 to USD 400.00 on October 21, 2026.
Amgen reported USD 10.05 billion in revenue for the second quarter of 2026.
Amgen stock costs EUR 393.95 at Lang & Schwarz on October 26, 2026 at 4:46 p.m. CEST, 1.71 percent below the Xetra close of October 23, 2026.
Amgen is scheduled to report third-quarter 2026 results on November 3, 2026.

Amgen, US0311621009, Illustration mit AI erstellt.

Barclays raised its price target for Amgen from USD 380.00 to USD 400.00 on October 21, 2026, while keeping an Equal-Weight rating, as reported by Benzinga. The target sits 9.94 percent below the USD 439.77 Amgen price on Nasdaq at 11:57 a.m. ET on October 26, 2026. Amgen stock was trading at EUR 393.95 at Lang & Schwarz on October 26, 2026 at 4:46 p.m. CEST, down EUR 6.85, or 1.71 percent, versus the Xetra close of October 23, 2026.

What does the target imply?

The latest analyst action leaves Barclays below Amgen's October 26 Nasdaq price, making the USD 400.00 target a measured valuation reference rather than an upward call. Benzinga lists 22 analysts in its consensus table, with a Neutral consensus rating and an average target of USD 389.00 on October 22, 2026.

Amgen's clinical pipeline remains a separate investor variable. MarketBeat reported on October 24, 2026 that IMDELLTRA plus IMFINZI reduced the risk of death by 58 percent in the DeLLphi-305 study. The same report said median progression-free survival rose from 1.90 months to 7.40 months, giving the result a measurable commercial and medical dimension.

Amgen's price position

On Nasdaq, Amgen last traded at USD 439.77 on October 26, 2026 at 11:57 a.m. ET while the market was open. The USD 288.00 to USD 450.98 52-week range places the stock 2.49 percent below its high, while the current market capitalization was USD 237.8 billion. The Nasdaq quote carried a price-to-earnings ratio of 27.36 and volume of 734,969 shares at that timestamp.

Valuation and next earnings date

Amgen reported USD 10.05 billion in revenue for the second quarter ended June 30, 2026, according to MarketBeat. The company is scheduled to report third-quarter 2026 results on November 3, 2026, after the market close, with the conference call set for 4:30 p.m. ET. MarketBeat lists consensus expectations of USD 10.08 billion in revenue and USD 5.79 in earnings per share for that quarter.

Comparison with peers

Amgen: down 1.71 percent versus the Xetra close, price-to-earnings ratio 27.36, market capitalization USD 237.8 billion as of October 26, 2026.

Biogen (NASDAQ, USD): down 0.40 percent, price-to-earnings ratio 44.22, market capitalization USD 36.9 billion as of October 26, 2026.

Gilead Sciences (NASDAQ, USD): up 1.56 percent, negative price-to-earnings ratio of 59.40, market capitalization USD 196.5 billion as of October 26, 2026.

Price stays below the Xetra close

Amgen's euro quotation was EUR 393.95 at Lang & Schwarz on October 26, 2026 at 4:46 p.m. CEST, down EUR 6.85, or 1.71 percent, versus the Xetra close of October 23, 2026 at EUR 400.80. The Nasdaq quotation and the analyst targets point to a stock trading near the upper end of its annual range, while the November 3 results date provides the next scheduled company checkpoint. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.